Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8- trifluoromethyl[1,2,4]triazolo[4,3- a ]pyridine (JNJ-42153605): A positive allosteric modulator of the metabotropic glutamate 2 receptor

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8770-8789

  Cid, Jose María ^a   Tresadern, Gary ^a   Vega, Juan Antonio ^a   De Lucas, Ana Isabel ^a   Matesanz, Encarnación ^a   Iturrino, Laura ^a   Linares, María Lourdes ^a   Garcia, Aránzazu ^a   Andrés, José Ignacio ^a   MacDonald, Gregor J ^a   Oehlrich, Daniel ^a   Lavreysen, Hilde ^a   Megens, Anton ^a   Ahnaou, Abdellah ^a   Drinkenburg, Wilhelmus ^a   MacKie, Claire ^a   Pype, Stefan ^a   Gallacher, David ^a   Trabanco, Andrés A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 3 CYCLOPROPYLMETHYL 7 (4 PHENYLPIPERIDIN 1 YL) 8 TRIFLUOROMETHYL[1,2,4]TRIAZOLO[4,3 A]PYRIDINE; 3 ETHYL 7 (4 PHENYLPIPERIDIN 1 YL) 8 TRIFLUOROMETHYL 1,2,4 TRIAZOLO[4,3 A]PYRIDINE; 8 CHLORO 3 CYCLOPROPYLMETHYL 7 (4 PHENYL 4 TRIFLUOROMETHYLPIPERIDIN 1 YL)[1,2,4]TRIAZOLO[4,3 A]PYRIDINE; 8 CHLORO 7 (4 FLUORO 4 PHENYLPIPERIDIN 1 YL) 3 (2,2,2-TRIFLUOROETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRIDINE; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; JNJ 42153605; LIGAND; METABOTROPIC RECEPTOR 2; MOLECULAR SCAFFOLD; NEUROLEPTIC AGENT; PHENCYCLIDINE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; ELECTROENCEPHALOGRAM; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; LOCOMOTION; MALE; NONHUMAN; RAT; REM SLEEP;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; CELL LINE; ELECTROENCEPHALOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; HYPERKINESIS; MALE; MICE; MICROSOMES, LIVER; PATCH-CLAMP TECHNIQUES; POLYSOMNOGRAPHY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SLEEP; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; WAKEFULNESS;

EID: 84867770282     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3010724     Document Type: Article

References (54)

1. Niswender, C. M.; Conn, J. P. Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322
2. Pilc, A.; Chaki, S.; Nowak, G.; Witkin, J. M. Mood disorders: regulation by metabotropic glutamate receptors Biochem. Pharmacol. 2008, 75, 997-1006
3. Lüscher, C.; Huber, K. M. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease Neuron 2010, 65, 445-459
4. Vinson, P. N.; Conn, P. J. Metabotropic glutamate receptors as therapeutic targets for schizophrenia Neuropharmacology 2012, 62, 1461-1472
5. Chiechio, S.; Nicoletti, F. Metabotropic glutamate receptors and the control of chronic pain Curr. Opin. Pharmacol. 2012, 12, 28-34
6. Foster, O. M. Metabotropic glutamate receptor ligands as potential therapeutics for addiction Curr. Drug Abuse Rev. 2009, 2, 83-98
7. Johnson, K. A.; Conn, P. J.; Niswender, C. M. Glutamate receptors as therapeutic targets for Parkinsons disease CNS Neurol. Disord.: Drug Targets 2009, 8, 475-491
8. Watkins, J. C. l -Glutamate as a central neurotransmitter: looking back Biochem. Soc. Trans. 2000, 28, 297-310
9. Kew, J. N. C.; Kemp, J. A. Ionotropic and metabotropic glutamate receptor structure and pharmacology Psyhopharmacology 2005, 179, 4-29
10. Huang, S.; Cao, J.; Jiang, M.; Labesse, G.; Liu, J.; Pin, J.-P.; Rondard, P. Interdomain movements in metabotropic glutamate receptor activation Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 15480-15485
11. Pin, J. P.; Galvez, T.; Prezeau, L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors Pharmacol. Ther. 2003, 98, 325-354
12. Brauner-Osborne, H.; Wellendorph, P.; Jensen, A. A. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors Curr. Drug Targets 2007, 8, 169-184
13. Cartmell, J.; Schoepp, D. D. Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 2000, 75, 889-907
14. Ohishi, H.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Distribution of the messenger RNA for metabotropic glutamate receptor, mGlu2, in the central nervous system of the rat Neuroscience 1993, 53, 1009-1018
15. 35S]GTPγS binding J. Comp. Neurol. 2005, 487, 15-27
16. Gu, G.; Lorrain, D. S.; Wei, H.; Cole, R. L.; Zhang, X.; Daggett, L. P.; Schaffhauser, H. J.; Bristow, L. J.; Lechner, S. M. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition Brain Res. 2008, 1197, 47-62
17. Ghose, S.; Gleason, K. A.; Potts, B. W.; Lewis-Amezcua, K.; Tamminga, C. A. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatry 2009, 166, 812-820
18. Shigeyuki, C.; Hirohiko, H. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia Curr. Pharm. Des. 2011, 17, 94-102
19. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C.R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L.; Griffey, K. R.; Tizzano, J. P.; Kallman, M. J.; Helton, D. R.; Schoepp, D. D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic roperties J. Med. Chem. 1997, 40, 528-537
20. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A. M.; Monn, J. A.; Schoepp, D. D. Glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discovery 2005, 4, 131-144
21. Fell, M. J.; McKinzie, D. L.; Monn, J. A.; Svensson, K. A. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia Neuropharmacology 2012, 62, 1473-1483
22. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Schoepp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat. Med. 2007, 13, 1102-1107
23. During the preparation of this manuscript Eli Lilly and Company announced in a press release (August 29, 2012) the decision to stop the clinical studies investigating LY2140023 for the treatment of patients suffering from schizophrenia. The press release mentioned that the decision was made after a recently conducted independent futility analysis concluded that HBBN, the second of Lillys two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. The decision was not based on any safety signals. https://investor.lilly.com/releaseDetail.cfm?ReleaseID=703018.
24. B receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors Mol. Pharmacol. 2001, 60, 881-884
25. B receptor desensitization Neuropharmacology 2008, 55, 1293-1299
26. Urwyler, S. Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63, 59-126
27. Trabanco, A. A.; Cid, J. M.; Lavreysen, H.; Macdonald, G. J.; Tresadern, G. Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2 Curr. Med. Chem. 2011, 18, 47-68
28. Trabanco, A. A.; Duvey, G.; Cid, J. M.; Macdonald, G. J.; Cluzeau, P.; Nhem, V.; Furnari, R.; Behaj, N.; Poulain, G.; Finn, T.; Lavreysen, H.; Poli, S.; Raux, A.; Thollon, Y.; Poirier, N.; DAddona, D.; Andres, J. I.; Lutjens, R.; Le Poul, E.; Imogai, H.; Rocher, J.-P. New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N -propyl-8-chloro-6-substituted isoquinolones Bioorg. Med. Chem. Lett. 2011, 21, 971-976
29. Trabanco, A. A.; Duvey, G.; Cid, J. M.; Macdonald, G. J.; Cluzeau, P.; Nhem, V.; Furnari, R.; Behaj, N.; Poulain, G.; Finn, T.; Poli, S.; Lavreysen, H.; Raux, A.; Thollon, Y.; Poirier, N.; DAddona, D.; Andrés, J. I.; Lutjens, R.; Le Poul, E.; Imogai, H.; Rocher, J.-P. New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): identification and synthesis of N -propyl-5-substituted isoquinolones Med. Chem. Commum. 2011, 2, 132-139
30. Cid, J. M.; Duvey, G.; Cluzeau, P.; Nhem, V.; Macary, K.; Raux, A.; Poirier, N.; Muller, J.; Bolea, C.; Finn, T.; Urios, I.; Epping-Jordan, M.; Chamelot, E.; Derouet, F.; Girard, F.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Lavreysen, H.; Linares, M. L.; Oehlrich, D.; Oyarzábal, J.; Tresadern, G.; Trabanco, A. A.; Andrés, J. I.; Le Poul, E.; Imogai, H.; Lutjens, R.; Rocher, J.-P. Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor ACS Chem. Neurosci. 2010, 1, 788-795
31. Imogai, H. J.; Cid-Nuñez, J. M.; Duvey, G. A. J.; Bolea, C. M.; Nhem, V.; Finn, T. P.; Le Poul, E. C.; Rocher, J.-P. F. C.; Lutjens, R. J. Novel Pyridinone Derivatives and Their Preparation, Pharmaceutical Compositions, and Use as Positive Allosteric Modulators of mGluR2-Receptors for Treatment of Various Neurological and Psychiatric Disorders. WO2006030032 A1, 2006.
32. Cid, J. M.; Duvey, G.; Tresadern, G.; Nhem, V.; Funary, R.; Cluzeau, P.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Alonso, J. M.; Linares, M. L.; Andrés, J. I.; Poli, S.; Lutjens, R.; Imogai, H.; Rocher, J.-P.; Macdonald, G. J.; Oehlrich, D.; Lavreysen, H.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.; Trabanco, A. A. Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor J. Med. Chem. 2012, 55, 2388-2405
33. Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J.; Duvey, G. A. J.; Lutjens, R. J. Preparation of 3-Cyano-4-(4-tetrahydropyran- phenyl)pyridin-2-one Derivatives as Positive mGluR2 Receptor Modulators. WO 2008107481 A1, 2008.
34. Imogai, H. I.; Cid-Nuñez, J. M.; Andrés-Gil, J. I.; Trabanco-Suárez, A. A.; Oyarzábal-Santamarina, J.; Dautzenberg, F. M.; Macdonald, G. J.; Pullan, S. E.; Lutjens, R. J.; Duvey, G. A. J.; Nhem, V.; Finn, T. P.; Melikyan, G. 1,4-Disubstituted 3-Cyanopyridone Derivatives and Their Use as Positive Allosteric Modulators of mGlu2-Receptors and Their Preparation. WO2007104783 A2, 2007.
35. Tresadern, G.; Cid, J. M; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; García, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.; Lavreysen, H.; Biesmans, I.; Trabanco, A. A. Scaffold hopping from pyridones to imidazo[1,2- a ]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor Bioorg. Med. Chem. Lett. 2010, 20, 175-179
36. Trabanco, A. A; Tresadern, G.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Garcia, A.; Linares, M. L.; Alonso de Diego, S. A.; Alonso, J. M.; Oehlrich, D.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.; Andres, J. I.; Lavreysen, H.; Cid, J. M. Imidazo[1,2- a ]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor J. Med. Chem. 2012, 55, 2688-2701
37. Cid-Nuñez, J. M.; Trabanco-Suárez, A. A.; Macdonald, G. J. Preparation of Indole and Benzoxazine Derivatives as Modulators of Metabotropic Glutamate Receptors for Treating Neurological and Psychiatric Disorders. WO 2010060589 A1, 2010.
38. Trabanco-Suárez, A. A.; Tresadern, G. J.; Vega-Ramiro, J. A.; Cid-Nuñez, J. M. Preparation of Imidazopyridine Derivatives for Use as mGluR2 Receptor Modulators. WO2009062676 A2, 2009.
39. Cid-Nuñez, J. M.; Oehlrich, D.; Trabanco-Suárez, A. A.; Tresadern, G. J.; Vega-Ramiro, J. A.; Macdonald, G. J. 1,2,4-Triazolo[4,3- a ]pyridine Derivatives and Their Use for the Treatment or Prevention of Neurological Disorders. WO2010130424 A1, 2010.
40. Cid-Nuñez, J. M.; De Lucas-Olivares, A. I.; Trabanco-Suárez, A. A.; Macdonald, G. J. 7-Aryl-1,2,4-triazolo[4,3- a ]pyridine Derivatives and Their Use as Positive Allosteric Modulators of mGluR2 Receptors. WO2010130423 A1, 2010.
41. Cid-Nuñez, J. M.; De Lucas-Olivares, A. I.; Trabanco-Suárez, A. A.; Macdonald, G. J. 1,2,4-Triazolo[4,3- a ]pyridine Derivatives and Their Use as Positive Allosteric Modulators of mGluR2 Receptors. WO2010130422 A1, 2010.
42. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
43. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
44. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discovery 2009, 8, 203-212
45. Tarcsay, A.; Nyiri, K.; Keseru, G. M. Impact of lipophilic efficiency on compound quality J. Med. Chem. 2012, 55, 1252-1260
46. Lopez-Rodriguez, F.; Medina-Ceja, L.; Wilson, C. L.; Jhung, D.; Morales-Villagram, A. Changes in extracellular glutamate levels in rat orbitofrontal cortex during sleep and wakefulness Arch. Med. Res. 2007, 38, 52-55
47. Ahnaou, A.; Dautzenberg, F. M.; Geys, H.; Imogai, H.; Gibelin, A.; Moechars, D.; Steckler, T.; Drinkenburg, W. H. I. M. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture Eur. J. Pharmacol. 2009, 603, 62-72
48. Feinberg, I.; Schoepp, D. D.; Hsieh, K.-C.; Darchia, N.; Campbell, I. G. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2 S -2-amino-2-(1 S,2 S -2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4, 6-dicarboxylate] in rats J. Pharmacol. Exp. Ther. 2005, 312, 826-833
49. Fell, M. J.; Witkin, J. M.; Falcone, J. F.; Katner, J. S.; Perry, K. W.; Hart, J.; Rorick-Kehn, L.; Overshiner, C. D.; Rasmussen, K.; Chaney, S. F.; Benvenga, M. J.; Deanna, X. L.; Marlow, L.; Thompson, L. K.; Luecke, S. K.; Wafford, K. A.; Seidel, W. F.; Edgar, D. M.; Quets, A. T.; Felder, C. C.; Wang, X.; Heinz, B. A.; Nikolayev, A.; Kuo, M.-S.; Mayhugh, D.; Khilevich, A.; Zhang, D.; Ebert, P. J.; Eckstein, J. A.; Ackermann, B. L.; Swanson, S. P.; Catlow, J. T.; Dean, R. A.; Jackson, K.; Tauscher-Wisniewski, S.; Marek, G. J.; Schkeryantz, J. M.; Svensson, K. A. N -(4-((2-(Trifluoromethyl)-3-hydroxy-4- (isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1 H -imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes J. Pharmacol. Exp. Ther. 2011, 336, 165-177
50. Siok, C. J.; Cogan, S. M.; Shifflett, L. B.; Doran, A. C.; Kocsis, B.; Hajós, M. Comparative analysis of the neurophysiological profile of group II metabotropic glutamate receptor activators and diazepam: effects on hippocampal and cortical EEG patterns in rats Neuropharmacology 2012, 62, 226-236
51. Gleason, S. D.; Shannon, H. E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice Psychopharmacology 1997, 129, 79-84
52. An internal report on the method is available upon request: Beerens, D. In Vitro Bacterial Reverse Mutation (Plate Incorporation) Assay with JNJ42153605-AAA in Salmonella typhimurium TA98; May 2009.
53. Tsutakawa, R. K. Statistical Methods in Bioassay. Estimation of Relative Potency from Quantal Responses. In Encyclopaedia of Statistical Science; Kotz, S.; Jonhson, N. L., Eds.; Wiley: New York, 1982.
54. 50) and Its Confidence Interval, Assuming a Linear Log Dose-Response Function. Internal Report N123705/1; Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, a Division of Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium, 1997.